FDA OKs New Schizophrenia, Bipolar Drug (Saphris)

By Smirnoff · Sep 22, 2009 · ·
  1. Smirnoff
    Aug. 14, 2009 -- The FDA has approved a new drug called Saphris to treat schizophrenia and bipolar I disorder in adults.
    "Mental illnesses like schizophrenia and bipolar disorder can be devastating to patients and families, requiring lifelong treatment and therapy," Thomas Laughren, MD, director of the division of psychiatry products in the FDA's Center for Drug Evaluation and Research, says in a news release.

    "Effective medicines can help people with mental illness live more independent lives," Laughren says.
    The FDA notes that the most common symptoms of schizophrenia include hearing voices or seeing things that are not there, having false beliefs (for example, believing that others are controlling thoughts, reading minds, or plotting harm), and being inappropriately suspicious or paranoid.

    Bipolar I disorder is a chronic, severe, and recurrent psychiatric disorder that causes alternating periods of depression and high, increased activity and restlessness, racing thoughts, fast talking, impulsive behavior, and a decreased need for sleep.
    Saphris, which comes in tablets, belongs to a class of drugs called atypical antipsychotics.

    The FDA approved Saphris based on clinical trials in which the drug trumped a placebo at reducing schizophrenia symptoms in adults and other trials in which Saphris was better than a placebo at treating symptoms of bipolar disorder.
    In clinical trials, the most common side effects reported by schizophrenia patients being treated with Saphris were the inability to sit still or remain motionless, decreased oral sensitivity, and drowsiness.

    The most common side effects in clinical trials of patients treated with Saphris for bipolar disorder were drowsiness, dizziness, movement disorders other than the inability to sit still or remain motionless, and weight gain.

    All atypical antipsychotic drugs carry a "black box" warning, the FDA's sternest warning, alerting prescrib
    ers about an increased risk of death associated with off-label use of these drugs to treat behavioral problems in older people with dementia-related psychosis. Saphris isn't approved for those patients.

    Saphris is made by the drug company Schering-Plough.


    Share This Article


  1. Synchronium
    For anyone else who decides to consult wikipedia regarding this new drug's mechanism of action.
  2. chibi curmudgeon
    Now wait just a cotton pickin' minute.

    So....about equal affinity, as an antagonist, for:

    8 serotonin receptors
    4 adrenergic
    4 dopamine
    AND 2 histamine.

    I hope I'm interpreting something wrong, because this sounds like an absolutely horrible drug with a ridiculous load of adverse effects.

    The drowsiness and dizziness are from the adrenergic and histamine receptors, weight gain is from histamine, and decreased oral sensitivity?? I don't even want to know. Good job NOT eliminating akathesia already associated with atypicals, too.

    Eat a dick, Schering. You could have foisted a useless me-too drug on the populace, but no, you decided to go with a harmful one. :applause:
  3. sveedish
    Beaver doesn't know if she's posting in the right place but can't find any info on the forum or on the net at large. Her gf is on 10 mg of saphris and 50 mg of zoloft, prescribed for mania and depression. She really wants to trip and has had disappointing trials with a few research chemicals. MXE seemed to work at a "normal" dosage but that's not really the kind of trip she wants, and she felt absolutely nothing from 25 mg of 2ci, with the exception of a little bit of stimulation.

    25 mg of 4-aco-dmt produced a short lived trip that peaked around 2.5 hours, at which point she tried to redose with 20mg insufflated. Which brought back the experience but not as strongly as it was initially. She saw a few squiggles of movement around the room on the 4acodmt, and enhanced colors, had some interesting insights and had fun, and felt like she was on a very low dose mushroom trip. However, she wants a full on trip. What research chemicals or other hallucinogens might be able to safely bypass the effects of the meds she is on? She wants a "classical" or prototypical trip...She's considering taking 50 milligrams of 4-aco-dmt orally.
  4. Rob Cypher
    I would not suggest trying to "up" a dose of a psychedelic simply to counter the lag effect from antipsychotics. You really shouldn't be using those two together - it's just going to cause problems with both substances in the long run (particularly regarding any positive effects one may be getting from using an antipsychotic).
  5. Valseedian
    the fact that both saphris and zoloft act as antagonists at ht2a and ht2c with really high binding affinities means that anyone who's taking them will have an incredibly hard time using halucinagens.. these 2 types of drugs shouldn't be mixed.

    you'll also find that even after quitting these drugs, you may have a difficult time tripping for some time afterwards.
  6. kailey_elise
    It's well-known that SSRIs (like, oh, Zoloft) often cause manic episodes when given to bipolar patients. *shakes head*

    As Val said, most psychedelics work on the serotonin receptors, and SSRIs (selective serotonin reuptake inhibitors) also affect them. Many (all?) atypical antipsychotics also affect the serotonin receptors.

To make a comment simply sign up and become a member!